GSK and Theravance set sights on early LABA/LAMA combo filing
This article was originally published in Scrip
Top-line data from four 24-week studies of GlaxoSmithKline and Theravance's LABA/LAMA combination are positive enough to warrant slightly earlier than planned global filings for regulatory approval for the treatment of chronic obstructive pulmonary disease (COPD) starting at the end of this year, the companies say. The markets responded mildly but positively to the news, with GSK's share price rising 1.7%, adding around £1.23 billion ($1.93 billion) to the company's market valuation.
You may also be interested in...
Novartis’s AveXis unit has received a CHMP nod for the spinal muscular atrophy gene therapy at its latest meeting, sending it on the final steps to market in the EU.
The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.
The German biotech firm has denied receiving any offer from the Trump administration in a wide-ranging conference call that also addressed recent changes at the top, its clinical timeline for a coronavirus vaccine and new funds from the European Commission to boost production.